# Rapid Response®

**Saliva Drug Test Stick**
(Oral Fluid)

Product Insert

**Instruction Sheet for testing of any combination of the following drugs:**

AMP/MET/COC/OPI/MOP/THC/PCP/MTD/MDMA/BZO/OXY/COT/K2/KET/BAR/BUP/TML/ 6-MAM/FYL/CFYL/MDPV/α-PVP/LSD/ALC

A rapid test for the simultaneous, qualitative detection of multiple drugs or drug metabolites and alcohol in human oral fluid. For healthcare professionals including professionals at point of care sites.
Immunoassay for *in vitro* diagnostic use only.

## Intended Use

The Rapid Response® Saliva Drug Test Stick is a lateral flow chromatographic immunoassay for the qualitative detection of multiple drugs or drug metabolites in human oral fluid at the following cut-off concentrations:

| Test | Calibrator | Cut-off (ng/mL) |
|---|---|---|
| Amphetamine (AMP) | d-Amphetamine | 50/40/25/20 |
| Methamphetamine (MET) | d-Methamphetamine | 50/30/25 |
| Marijuana (THC) | 11-nor-$\Delta^9$ -THC-9 COOH | 50/40/30/25/ 20/15/12 |
| Phencyclidine (PCP) | Phencyclidine | 10 |
| Cocaine (COC) | Benzoylecgonine | 50/40/30/20 |
| Opiates/Morphine (OPI/MOP) | Morphine | 50/40/25/20/ 10 |
| Methadone (MTD) | Methadone | 50/30 |
| Methylenedioxymethamphetamine (MDMA) | d,l-Methylenedioxyme-thamphetamine | 75/50 |
| Oxycodone (OXY) | Oxycodone | 50/40/20 |
| Cotinine (COT) | Cotinine | 20 |
| Benzodiazepines (BZO) | Oxazepam | 50/30/20/10 |
| Synthetic Marijuana (K2) | JWH-018, JWH-073 | 25 |
| Ketamine (KET) | Ketamine | 150/100/50 |
| Barbiturates (BAR) | Secobarbital | 50 |
| Buprenorphine (BUP) | Buprenorphine | 10/5 |
| Tramadol (TML) | Tramadol | 30 |
| 6-Monoacetylmorphine (6-MAM) | 6-Monoacetylmorphine | 10 |
| Fentanyl (FYL) | Fentanyl | 50/20/10 |
| Carfentanyl (CFYL) | Carfentanyl | 50 |
| 3, 4-methylenedioxypyrovalerone (MDPV) | 3, 4-methylenedioxy-pyrovalerone | 300 |
| alpha-Pyrrolidinovalerophenone (α-PVP) | alpha-Pyrrolidinovalerophenone | 300 |
| Lysergic Acid Diethylamide (LSD) | Lysergic Acid Diethylamide | 10 |
| **Test** | **Calibrator** | **Cut-off** |
| Alcohol(ALC) | Alcohol | 0.02% |

This assay provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory methods. Professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

**WARNING:** This testing device is not licensed for drug checking prior to consumption. When used for this purpose, there is a risk of inaccurate results.

## Summary

The Rapid Response® Saliva Drug Test Stick is a rapid, oral fluid screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in human oral fluid.

**Amphetamine (AMP)**
Amphetamine is a sympathomimetic amine with therapeutic indications. The drug is often self-administered by nasal inhalation or oral ingestion. Depending on the route of administration, amphetamine can be detected in oral fluid as early as 5-10 minutes following use.[1] Amphetamine can be detected in oral fluid for up to 72 hours after use.[1]

**Methamphetamine (MET)**
Methamphetamine is a potent stimulant chemically related to amphetamine but with greater CNS stimulation properties. The drug is often self-administered by nasal inhalation, smoking or oral ingestion. Depending on the route of administration, methamphetamine can be detected in oral fluid as early as 5-10 minutes following use.[1] Methamphetamine can be detected in oral fluid for up to 72 hours after use.[1]

**Cocaine (COC)**
Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic derived from the coca plant (erythroxylum coca). The drug is often self-administered by nasal inhalation, intravenous injection and free-base smoking. Depending on the route of administration, cocaine and metabolites benzoylecgonine and ecgonine methyl ester can be detected in oral fluid as early as 5-10 minutes following use.[1] Cocaine and benzoylecgonine can be detected in oral fluid for up to 24 hours after use.[1]

**Opiates (OPI/MOP)**
The drug class opiates refers to any drug that is derived from the opium poppy, including naturally occurring compounds such as morphine and codeine and semi-synthetic drugs such as heroin. Opiates act to control pain by depressing the central nervous system. The drugs demonstrate addictive properties when used for sustained periods of time; symptoms of withdrawal may include sweating, shaking, nausea and irritability. Opiates can be taken orally or by injection routes including intravenous, intramuscular and subcutaneous; illegal users may also take the intravenously or by nasal inhalation. Using an immunoassay cutoff level of 40ng/ml, codeine can be detected in the oral fluid within 1 hour following a single oral dose and can remain detectable for 7-21 hours after the dose.[1] Heroin metabolite 6-monoacetylmorphine (6-MAM) is found more prevalently in excreted unmetabolized, and is also the major metabolic product of codeine and heroin.[2]

**Marijuana (THC)**
11-nor-$\Delta^9$-tetrahydrocannabinol-9-carboxylic acid ($\Delta^9$-THC-COOH), the metabolite of THC ($\Delta^9$-tetrahydrocannabinol), is detectable in oral fluid shortly after use. The detection of the drug is thought to be primarily due to the direct exposure of the drug to the mouth (oral and smoking administrations) and the subsequent sequestering of the drug in the buccal cavity.[3] Historical studies have shown a window of detection for THC in oral fluid of up to 14 hours after drug use.[3]

**Phencyclidine (PCP)**
Phencyclidine, the hallucinogen commonly referred to as Angel Dust, can be detected in oral fluid as a result of the exchange of the drug between the circulatory system and the oral cavity. In a paired serum and oral fluid sample collection of 100 patients in an Emergency Department, PCP was detected in the oral fluid of 79 patients at levels as low as 2ng/mL and as high as 600ng/mL.[4]

**Methadone (MTD)**
Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine).
Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.[1]

**Methylenedioxymethamphetamine (MDMA)**
Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity. Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws.[1]

**Oxycodone (OXY)**
Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin®, Tylox®, Percodan® and Percocet®. While Tylox®, Percodan® and Percocet® contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form. Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone.

**Cotinine (COT)**
Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays.
Although nicotine is excreted in oral fluid, the relatively short half-life of the drug makes it an unreliable maker for tobacco use. Cotinine, however, demonstrates a substantially longer half-life than nicotine bears a high correlation with plasma cotinine levels and has been found to be the best maker for smoking status compared with oral fluid nicotine measurement, breath carbon monoxide testing and plasma thiocyanate testing. The window of detection for cotinine in oral fluid test is expected to be up to 1-2 days after nicotine use.

**Benzodiazepines (BZO)**
Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, Benzodiazepines have replaced Barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal. Risk of physical dependence increases if Benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.[1]

**Synthetic Marijuana (K2)**
Synthetic Marijuana or K2 is a psychoactive herbal and chemical product that, when consumed, mimics the effects of Marijuana. It is best known by the brand names K2 and Spice, both of which have largely become genericized trademarks used to refer to any synthetic Marijuana product. The studies suggest that synthetic marijuana intoxication is associated with acute psychosis, worsening of previously stable psychotic disorders, and also may have the ability to trigger a chronic (long-term) psychotic disorder among vulnerable individuals such as those with a family history of mental illness.[6]
Elevated levels of oral fluid metabolites are found within hours of exposure and remain detectable window up to 24-48 hours after smoking (depending on usage/dosage).

**Ketamine (KET)**
Ketamine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia and veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates similar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or blocked speech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function but not of the central nervous system, and cardiovascular function is maintained.[7] The effects of Ketamine generally last 4-6 hours following use.

**Barbiturates (BAR)**
Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.[8]
Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.
The approximate detection time limits for barbiturates are:

| | | |
|---|---|---|
| Short acting (e.g. Secobarbital) | 100 mg PO (oral) | 4.5 |
| Long acting (e.g. Phenobarbital) | 400 mg PO (oral) | 7 days[2] |

**Buprenorphine (BUP)**
Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. The elimination half-life of buprenorphine is 20–73 hours (mean 37). Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has

been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and inhalation routes

**Tramadol (TML)**

Tramadol (TML) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. Large doses of tramadol can develop tolerance and physiological dependency and lead to its abuse. Tramadol is extensively metabolized after oral administration. Approximately 30% of the dose is excreted in oral fluid as unchanged drug, whereas 60% is excreted as metabolites. The major pathways appear to be N- and O- demethylation, glucoronidation or sulfation in the liver.

**6-Monoacetylmorphine (6-MAM)**

6-Monoacetylmorphine (6-MAM) or 6-acetylmorphine (6-MAM) is one of three active metabolites of heroin (diacetylmorphine), the others being morphine and the much less active 3-monoacetylmorphine (3-MAM). 6-MAM is rapidly created from heroin in the body, and then is either metabolized into morphine or excreted in the oral fluid. 6-MAM remains in the oral fluid for no more than 24 hours. So a oral fluid specimen must be collected soon after the last heroin use, but the presence of 6-MAM guarantees that heroin was in fact used as recently as within the last day. 6-MAM is naturally found in the brain,5 but in such small quantities that detection of this compound in oral fluid virtually guarantees that heroin has recently been consumed.

**Fentanyl (FYL)**

Fentanyl, belongs to powerful narcotics analgesics, and is a special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations "Single Convention of narcotic drug in 1961". Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain.5 After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as ataxia and irritability etc,[6,7] which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of amphetamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose.[8]

**Carfentanyl (CFYL)**

Carfentanyl is an analog of the synthetic opioid analgesic fentanyl. It is 10,000 times more potent than morphine, making it among the most potent commercially used opioids. Carfentanyl was first synthesized in 1974.[9] It is marketed under the trade name Wildnil as a general anaesthetic agent for large animals.[10] Side effects of carfentanyl are similar to those of fentanyl, which include itching, nausea and respiratory depression, which can be life-threatening.[11] Carfentanyl is classified as Schedule II under the Controlled Substances Act in the United States with a DEA ACSCN of 9743.

**3, 4-methylenedioxypyrovalerone (MDPV)**

3,4-methylenedioxypyrovalerone (MDPV) is a psychoactive recreational drug with stimulant properties which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was first developed in the 1960s by a team at Boehringer Ingelheim.1 MDPV remained an obscure stimulant until around 2004 when it was reportedly sold as a designer drug. Products labeled as bath salts containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing for Spice and K2 as incense.

MDPV is the 3,4-methylenedioxy ring-substituted analog of the compound pyrovalerone, developed in the 1960s, which has been used for the treatment of chronic fatigue and as an anorectic, but caused problems of abuse and dependence. However, despite its structural similarity, the effects of MDPV bear little resemblance to other methylenedioxy phenylalkylamine derivatives such as 3,4-methylenedioxy-N-methylamphetamine (MDMA), instead producing primarily stimulant effects with only mild entactogenic qualities.[12]

MDPV undergoes CYP450 2D6, 2C19, 1A2, and COMT phase 1 metabolism (liver) into methylcatechol and pyrrolidine, which in turn are glucuronated (uridine 5'-diphospho-glucuronosyl-transferase) allowing it to be excreted by the kidneys, with only a small fraction of the metabolites being excreted into the stools.[13] No free pyrrolidine will be detected in the oral fluid.

**alpha-Pyrrolidinovalerophenone (α-PVP)**

alpha-Pyrrolidinovalerophenone (also known as α-PVP, A-PVP, alpha-PVP, and Flakka) is a synthetic stimulant substance of the cathinone and pyrrolidine chemical classes. α-PVP may be quantified in blood, plasma or urine to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation.[14] It generally comes in the form of either a crystalline powder or crystallized shards which users can ingest to produce powerful but short-lived euphoric stimulant effects which are comparable to those of methamphetamine and cocaine when insufflated or vaporized. α-PVP has been reported to be the cause, or a significant contributory cause of death in suicides and overdoses caused by combinations of drugs.[15] It has also been linked to at least one death where it was combined with pentedrone and caused heart failure.

**Lysergic Acid Diethylamide (LSD)**

Lysergic acid diethylamide (LSD) is a white powder or a clear, colourless liquid. LSD is manufactured from lysergic acid which occurs naturally in the ergot fungus that grows on wheat and rye. It is a Schedule I controlled substance, available in liquid, powder, tablet (microdots), and capsule form. LSD is recreationally used as a hallucinogen for its ability to alter human perception and mood. LSD is primarily used by oral administration, but can be inhaled, injected, and transdermally applied. LSD is a non-selective 5-HT agonist, may exert its hallucinogenic effect by interacting with 5-HT 2Areceptors as a partial agonist and modulating the NMDA receptor-mediated sensory, perceptual, affective and cognitive processes. LSD mimics 5-HT at 5-HT 1A receptors, producing a marked slowing of the firing rate of serotonergic neurons. LSD has a plasma half-life of 2.5-4 hours. Metabolites of LSD include N-desmethyl-LSD, hydroxy-LSD, 2-oxo-LSD and 2-oxo-3-hydroxy-LSD.These metabolites are all inactive.

**Alcohol (ALC)**

Two-thirds of all adults drink alcohol.16 The blood alcohol concentration at which a person becomes impaired is variable dependent upon the individual. Each individual has specific parameters that affect the level of impairment such as size, weight, eating habits and alcohol tolerance. Inappropriate consumption of alcohol can be a contributing factor to many accidents, injuries, and medical conditions.[17]

## Assay Principle

The Rapid Response® Saliva Drug Test Stick is an immunoassay based on the principle of competitive binding. Drugs that may be present in the oral fluid specimen compete against their respective drug conjugate for binding sites on their specific antibody.

During testing, a portion of the oral fluid specimen migrates upward by capillary action. A drug, if present in the oral fluid specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible coloured line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration in the oral fluid specimen will saturate all the binding sites of the antibody. Therefore, the coloured line will not form in the test line region.

A drug-positive oral fluid specimen will not generate a coloured line in the specific test line region of the strip because of drug competition, while a drug-negative oral fluid specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a coloured line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

## Alcohol Principle

The Oral Fluid Alcohol Rapid Test consists of a plastic strip with a reaction pad attached at the tip. On contact with solutions of alcohol, the reaction pad will rapidly turn colours depending on the concentration of alcohol present. The pad employs a solid-phase chemistry which uses a highly specific enzyme reaction.

## Reagents

Each test contains membrane strips coated with drug-protein conjugates (purified bovine albumin) on the test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibody specific to corresponding drug.

## Alcohol Reagents

Tetramethylbenzidine/Alcohol Oxidase (EC 1.1.3.13)/Peroxidase (EC 1.11.1.7)/ Other additives

## Precautions

- For healthcare professional and clinical *in vitro* diagnostic use only.
- Do not use after the expiration date.
- The test should remain in the sealed pouch until use.
- Oral fluid is not classified as biological hazard unless derived from a dental procedure.
- The used Device should be discarded according to local regulations.

## Alcohol Precautions

Test materials that have been exposed to oral fluid should be treated as potentially infectious. Do not use the Oral fluid Alcohol Rapid Test after the expiration date marked on the foil package.

## Materials

### Materials provided

- Test devices
- ALC colour chart (when applicable)
- Product insert

### Materials required but not provided

- Timer

## Storage and Stability

Store as packaged in the sealed pouch at 2-30°C (35.6-86°F). The test is stable through the expiration date printed on the sealed pouch. The test Device must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

## Alcohol Storage and stability

The Alcohol Rapid Test is to be stored at 2-30°C (35.6-86°F) in its sealed foil package. If storage temperatures exceed 30°C (86°F), the test performance may degrade. If the product is refrigerated, the Oral fluid Alcohol Rapid Test must be brought to room temperature prior to opening the pouch.

## Collection and Storage of Specimens

- The oral fluid specimen should be collected using the device with the kit. Follow the detailed Directions for Use below. No other collection device should be used with this assay. Oral fluid collected at any time of the day may be used.

## Directions For Use

**Allow the test device, specimen and/or controls to reach room temperature (59-86°F; 15-30°C) prior to testing. Instruct the donor to not place anything in the mouth including food, drink, gum or tobacco products for at least 10 minutes prior to collection.**

1. Bring the pouch to room temperature before opening it. Remove the test from the sealed pouch and use it within one hour.
2. Take off the Device cap and collect oral fluid specimen as follows.
   a) **IMPORTANT:** Place the absorbent wick against the upper, lower jaws and roots to enrich the oral fluid. Insert the sponge end into the mouth, actively swab around the gums on both sides of the mouth (10-15 times) to assist saturation.
   b) Put the absorbent wick under the tongue to collect oral fluid until the flow appear in the test windows (approximately 60 seconds) and then take out the device and start a timer.
   c) If no flow appeared repeat the procedures in steps above until the flow appear. If no flow appeared after triplicate of steps above, discard the device, review procedures with the donor and repeat the test using a new device.
   d) Place the test device on a clean and level surface.
3. Read the test result at **3-10 minutes**.
4. If all lines are clearly visible at 3 minutes or sooner, then the test can be interpreted as negative and discarded. If any lines are not visible at 3 minutes, then the test should be re-read at 10 minutes.
5. Alcohol indicator, when applicable, the result should be read at 3-5 minutes. Compare the colour of the reaction pad with the colour chart provided separately/on foil pouch to determine the relative oral fluid alcohol level.






## Results Interpretation




**NEGATIVE:* A coloured line appears in the control region (C) and another coloured line appears in the test region (T).** This negative result means that the concentrations in the oral fluid sample are below the designated cut-off levels for a particular drug tested.
***NOTE:** The shade of the coloured lines(s) in the Test regions (T) may vary. The result should be considered negative whenever there is even a faint line.




**POSITIVE: A coloured line appears in the control region (C) and no line appears in the test region (T).** The positive result means that the drug concentration in the oral fluid sample is greater than the designated cut-off for a specific drug.




**INVALID: No line appears in the control region (C).** Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for Control line failure. Read the directions again and repeat the test with a new test device. If the result is still invalid, contact your manufacturer.

### Alcohol Strip Interpretation

**Positive:** The Oral Fluid Alcohol Rapid Test will produce a colour change in the presence of oral fluid alcohol. The colour will range from light blue colour at 0.02% relative oral fluid alcohol concentration to a dark blue colour near 0.30% relative oral fluid alcohol concentration. Colour pads are provided within this range to allow an approximation of relative oral fluid alcohol concentration. The test may produce colours that appear to be between adjacent colour pads.
**NOTE:** The Oral fluid Alcohol Rapid Test is very sensitive to the presence of alcohol. A blue colour that is lighter than the 0.02% colour pad should be interpreted as being positive to the presence of alcohol in oral fluid.
**Negative:** When the oral fluid Alcohol Rapid Test shows no colour change this should be interpreted as a negative result indicating that alcohol has not been detected.
**Invalid:** If the colour pad has a blue colour before applying oral fluid sample, do not use the test.
**NOTE:** A result where the outer edges of the colour pad produces a slight colour but the majority of the pad remains colourless the test should be repeated to ensure complete saturation of the pad with oral fluid. The test is not reusable.

## Quality Control

A procedural control is included in the test. A coloured line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

## Limitations

1. The Rapid Response® Saliva Drug Test Stick provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas Chromatography/Mass Spectrometry (GC/MS) is preferred confirmatory methods.18
2. A positive test result does not indicate the concentration of drug in the specimen or the route of administration.
3. A negative result may not necessarily indicate a drug-free specimen. Drug may be present in the specimen below the cutoff level of the assay.

## Alcohol Limitation

1. The Oral Fluid Alcohol Rapid Test is highly sensitive to the presence of alcohol. Alcohol vapors in the air are sometimes detected by the Oral Fluid Alcohol Rapid Test. Alcohol vapors are present in many institutions and homes. Alcohol is a component in many household products such as disinfectant, deodorizers, perfumes, and glass cleaners. If the presence of alcohol vapors is suspected, the test should be performed in an area known to be free of vapors.
2. Ingestion or general use of over-the-counter medications and products containing alcohol can produce positive results.

## Performance Characteristics

### Analytical Sensitivity

Drug-free oral fluid was spiked with drugs to target concentrations of ±50% cut-off, ±25% cut-off and +300% cut-off and tested with the Rapid Response® Saliva Drug Test Stick. The results are summarized below.

| Drug Concentration Cut-off Range | AMP 50 | | MET 50 | | MET 25 | | THC 50 | | COT 20 | | BZO 50 | | PCP 10 | | FYL 50 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 28 | 2 | 28 | 2 | 27 | 3 | 25 | 5 | 25 | 5 | 25 | 5 | 27 | 3 |
| Cut-off | 15 | 15 | 16 | 14 | 16 | 14 | 12 | 18 | 20 | 10 | 13 | 17 | 14 | 16 | 15 | 15 |
| +25% Cut-off | 7 | 23 | 6 | 24 | 6 | 24 | 8 | 22 | 7 | 23 | 4 | 26 | 10 | 20 | 8 | 22 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | TML 30 | | FYL 20 | | FYL 10 | | CFYL 50 | | BZO 30 | | MDPV 300 | | α-PVP 300 | | LSD 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 26 | 4 | 26 | 4 | 25 | 5 | 25 | 5 | 27 | 3 | 26 | 4 | 26 | 4 |
| Cut-off | 13 | 17 | 15 | 15 | 15 | 15 | 15 | 15 | 13 | 17 | 20 | 10 | 19 | 11 | 16 | 14 |
| +25% Cut-off | 7 | 23 | 3 | 27 | 3 | 27 | 7 | 23 | 4 | 26 | 4 | 26 | 6 | 24 | 7 | 23 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | OPI/ MOP 40 | | K2 25 | | MTD 30 | | MTD 50 | | OXY 20 | | MDMA 50 | | BZO 20 | | OXY 50 | | OPI/ MOP 25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 26 | 4 | 25 | 5 | 25 | 5 | 27 | 3 | 26 | 4 | 25 | 5 | 26 | 4 | 27 | 3 |
| Cut-off | 13 | 17 | 15 | 15 | 15 | 15 | 15 | 15 | 20 | 10 | 19 | 11 | 13 | 17 | 15 | 15 | 13 | 17 |
| +25% Cut-off | 7 | 23 | 3 | 27 | 7 | 23 | 7 | 23 | 4 | 26 | 6 | 24 | 4 | 26 | 6 | 24 | 7 | 23 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | COC 20 | | 6-MAM 10 | | BUP 10 | | THC 12 | | BAR 50 | | KET 50 | | BZO 10 | | THC 20 | | OPI/ MOP 50 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 28 | 2 | 26 | 4 | 27 | 3 | 25 | 5 | 26 | 4 | 25 | 5 | 27 | 3 | 27 | 3 |
| Cut-off | 15 | 15 | 20 | 10 | 14 | 16 | 12 | 18 | 18 | 12 | 14 | 16 | 14 | 16 | 12 | 18 | 13 | 17 |
| +25% Cut-off | 8 | 22 | 2 | 28 | 10 | 20 | 8 | 22 | 8 | 22 | 10 | 20 | 4 | 26 | 8 | 22 | 7 | 23 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | COC 50 | | THC 40 | | THC 15 | | OXY 40 | | KET 100 | | MDMA 75 | | KET 150 | | THC 25 | | AMP 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 27 | 3 | 27 | 3 | 26 | 4 | 26 | 4 | 26 | 4 | 27 | 3 | 29 | 1 | | |
| Cut-off | 15 | 15 | 12 | 18 | 12 | 18 | 15 | 15 | 14 | 16 | 19 | 11 | 14 | 16 | 12 | 18 | 15 | 15 |
| +25% Cut-off | 8 | 22 | 8 | 22 | 8 | 22 | 6 | 24 | 10 | 20 | 6 | 24 | 10 | 20 | 8 | 22 | 10 | 20 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | OPI/ MOP 20 | | COC 30 | | AMP 40 | | MET 30 | | THC 30 | | COC 40 | | OPI/ MOP 10 | | AMP 25 | | BUP 5 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 27 | 3 | 27 | 3 | 28 | 2 | 27 | 3 | 21 | 9 | 27 | 3 | 27 | 3 | 26 | 4 |
| Cut-off | 13 | 17 | 15 | 15 | 15 | 15 | 16 | 14 | 12 | 18 | 17 | 13 | 13 | 17 | 15 | 15 | 14 | 16 |
| +25% Cut-off | 7 | 23 | 8 | 22 | 7 | 23 | 6 | 24 | 8 | 22 | 8 | 22 | 7 | 23 | 7 | 23 | 10 | 20 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

### Analytical Specificity

The following table lists the concentration of compounds (ng/mL) above which the Rapid Response® Saliva Drug Test Stick identified positive results at a read time of 3-10 minutes.

| Compound | ng/mL |
|---|---|
| **Amphetamine (AMP 50)** | |
| d-Amphetamine | 50 |
| d/l-Amphetamine | 100 |
| p-Hydroxyamphetamine | 100 |
| (+)3,4-Methylenedioxyamphetamine (MDA) | 100 |
| ß-Phenylethylamine | 25,000 |
| l-Amphetamine | 25,000 |
| Methoxyphenamine | 12,500 |
| Tryptamine | 12,500 |
| **Amphetamine (AMP 40)** | |
| d-Amphetamine | 40 |
| d/l-Amphetamine | 80 |
| p-Hydroxyamphetamine | 80 |
| (+)3,4-Methylenedioxyamphetamine (MDA) | 80 |
| ß-Phenylethylamine | 20,000 |
| l-Amphetamine | 20,000 |
| Methoxyphenamine | 10,000 |
| Tryptamine | 10,000 |
| **Amphetamine (AMP 25)** | |
| d-Amphetamine | 25 |
| d/l-Amphetamine | 50 |
| p-Hydroxyamphetamine | 50 |
| (+)3,4-Methylenedioxyamphetamine (MDA) | 50 |
| ß-Phenylethylamine | 12,500 |
| l-Amphetamine | 12,500 |
| Methoxyphenamine | 6,250 |
| Tryptamine | 6,250 |
| **Amphetamine (AMP 20)** | |
| d-Amphetamine | 20 |
| d/l-Amphetamine | 40 |
| p-Hydroxyamphetamine | 40 |
| (+)3,4-Methylenedioxyamphetamine (MDA) | 40 |
| ß-Phenylethylamine | 10,000 |
| l-Amphetamine | 10,000 |
| Methoxyphenamine | 5,000 |
| Tryptamine | 5,000 |
| **Methamphetamine (MET 50)** | |
| d-Methamphetamine | 50 |
| Fenfluramine | 60,000 |
| p-Hydroxymethamphetamine | 400 |
| Methoxyphenamine | 25,000 |
| 3,4-Methylenedioxymethamphetamine (MDMA) | 50 |
| l-Phenylephrine (R)-(-)-Phenylephrine | 6,250 |
| Procaine | 2,000 |
| (1R,2S) - (-) Ephedrine | 400 |
| Ephedrine | 400 |
| Benzphetamine | 25,000 |
| Mephentermine | 1,500 |
| **Methamphetamine (MET 30)** | |
| d-Methamphetamine | 30 |
| Fenfluramine | 36,000 |
| p-Hydroxymethamphetamine | 250 |
| Methoxyphenamine | 15,000 |
| 3,4-Methylenedioxymetham-phetamine (MDMA) | 30 |
| l-Phenylephrine (R)-(-)-Phenylephrine | 3,750 |
| Procaine | 1,200 |
| (1R,2S) - (-) Ephedrine | 250 |
| Ephedrine | 250 |
| Benzphetamine | 15,000 |
| Mephentermine | 900 |
| **Methamphetamine (MET 25)** | |
| d-Methamphetamine | 25 |
| Fenfluramine | 30,000 |
| p-Hydroxymethamphetamine | 200 |
| Methoxyphenamine | 12,500 |
| 3,4-Methylenedioxymetham-phetamine (MDMA) | 25 |
| l-Phenylephrine (R)-(-)-Phenylephrine | 3,500 |
| Procaine | 1,000 |
| (1R,2S) - (-) Ephedrine | 200 |
| Ephedrine | 200 |
| Benzphetamine | 12,500 |
| Mephentermine | 750 |
| **Marijuana (THC 50)** | |
| 11-nor- $\Delta^9$ -THC-9 COOH | 50 |
| Cannabinol | 50,000 |
| 11-nor- $\Delta^8$-THC-9 COOH | 40 |
| $\Delta^8$ -THC | 25,000 |

| Compound | ng/mL |
|---|---|
| $\Delta^9$ -THC | 40,000 |
| **Marijuana (THC 40)** | |
| 11-nor- $\Delta^9$ -THC-9 COOH | 40 |
| Cannabinol | 40,000 |
| 11-nor- $\Delta^8$ -THC-9 COOH | 32 |
| $\Delta^8$ -THC | 20,000 |
| $\Delta^9$ -THC | 32,000 |
| **Marijuana (THC 30)** | |
| 11-nor- $\Delta^9$ -THC-9 COOH | 30 |
| Cannabinol | 30,000 |
| 11-nor- $\Delta^8$-THC-9 COOH | 25 |
| $\Delta^8$ -THC | 15,000 |
| $\Delta^9$-THC | 24,000 |
| **Marijuana (THC 25)** | |
| 11-nor- $\Delta^9$-THC-9 COOH | 25 |
| Cannabinol | 20,000 |
| 11-nor- $\Delta^8$-THC-9 COOH | 25 |
| $\Delta^8$-THC | 10,000 |
| $\Delta^9$-THC | 17,000 |
| **Marijuana (THC 20)** | |
| 11-nor- $\Delta^9$-THC-9 COOH | 20 |
| Cannabinol | 20,000 |
| 11-nor- $\Delta^8$-THC-9 COOH | 15 |
| $\Delta^8$-THC | 10,000 |
| $\Delta^9$-THC | 17,000 |
| **Marijuana (THC 15)** | |
| 11-nor- $\Delta^9$-THC-9 COOH | 15 |
| Cannabinol | 12,500 |
| 11-nor- $\Delta^8$-THC-9 COOH | 12 |
| $\Delta^8$-THC | 6,000 |
| $\Delta^9$-THC | 10,000 |
| **Marijuana (THC 12)** | |
| 11-nor- $\Delta^9$-THC-9 COOH | 12 |
| Cannabinol | 12,500 |
| 11-nor- $\Delta^8$-THC-9 COOH | 12 |
| $\Delta^8$-THC | 6,000 |
| $\Delta^9$-THC | 10,000 |
| **Cocaine (COC 50)** | |
| Benzoylecgonine | 50 |
| Cocaine | 50 |
| Cocaethylene | 75 |
| Ecgonine | 3,750 |
| Ecgonine methyl ester | 30,000 |
| **Cocaine (COC 40)** | |
| Benzoylecgonine | 40 |
| Cocaine | 40 |
| Cocaethylene | 30 |
| Ecgonine | 3,000 |
| Ecgonine methyl ester | 25,000 |
| **Cocaine (COC 30)** | |
| Benzoylecgonine | 30 |
| Cocaine | 30 |
| Cocaethylene | 45 |
| Ecgonine | 2,250 |
| Ecgonine methyl ester | 18,750 |

| Compound | ng/mL |
|---|---|
| **Cocaine (COC 20)** | |
| Benzoylecgonine | 20 |
| Cocaine | 20 |
| Cocaethylene | 30 |
| Ecgonine | 1,500 |
| Ecgonine methyl ester | 12,500 |
| **Opiates/Morphine (OPI/MOP 50)** | |
| Morphine | 50 |
| Codeine | 30 |
| Ethylmorphine | 30 |
| Hydromorphine | 125 |
| Hydrocodone | 125 |
| Diacetylmorphine(Heroin) | 50 |
| Oxycodone | 30,000 |
| Morphine 3-β-D-Glucuronide | 50 |
| Norcodeine | 6,500 |
| Normorphine | 30,000 |
| Nalorphine | 12,500 |
| Oxymorphone | 30,000 |
| Thebaine | 2,500 |
| Levorphanol | 600 |
| 6-Monoacetylmorphine | 30 |
| **Opiates/Morphine (OPI/MOP 40)** | |
| Morphine | 40 |
| Codeine | 25 |
| Ethylmorphine | 25 |
| Hydromorphine | 100 |
| Hydrocodone | 100 |
| Diacetylmorphine (Heroin) | 50 |
| Oxycodone | 25,000 |
| Morphine 3-β-D-Glucuronide | 50 |
| Norcodeine | 6,250 |
| Normorphine | 25,000 |
| Nalorphine | 10,000 |
| Oxymorphone | 25,000 |
| Thebaine | 2,000 |
| Levorphanol | 400 |
| 6-Monoacetylmorphine | 25 |
| **Opiates/Morphine (OPI/MOP 25)** | |
| Morphine | 25 |
| Codeine | 20 |
| Ethylmorphine | 20 |
| Hydromorphine | 70 |
| Hydrocodone | 70 |
| Levorphanol | 300 |
| Oxycodone | 17,000 |
| 6-Monoacetylmorphine | 20 |
| Morphine 3-β-D-Glucuronide | 40 |
| Norcodeine | 4,250 |
| Normorphine | 17,000 |
| Nalorphine | 7,000 |
| Oxymorphone | 17,000 |
| Thebaine | 1,500 |
| Diacetylmorphine (Heroin) | 40 |
| **Opiates/Morphine (OPI/MOP 20)** | |
| Morphine | 20 |

| Compound | ng/mL |
|---|---|
| Codeine | 15 |
| Ethylmorphine | 15 |
| Hydromorphine | 50 |
| Hydrocodone | 50 |
| Levorphanol | 200 |
| Oxycodone | 12,500 |
| 6-Monoacetylmorphine | 15 |
| Morphine 3-β-D-Glucuronide | 25 |
| Norcodeine | 3,200 |
| Normorphine | 12,500 |
| Nalorphine | 5,000 |
| Oxymorphone | 12,500 |
| Thebaine | 1,000 |
| Diacetylmorphine (Heroin) | 25 |
| **Opiates/Morphine (OPI/MOP 10)** | |
| Morphine | 10 |
| Codeine | 12 |
| Ethylmorphine | 12 |
| Hydromorphine | 30 |
| Hydrocodone | 30 |
| Levorphanol | 150 |
| Oxycodone | 10,000 |
| 6-Monoacetylmorphine | 12 |
| Morphine 3-β-D-Glucuronide | 20 |
| Norcodeine | 2,500 |
| Normorphine | 10,000 |
| Nalorphine | 3,000 |
| Oxymorphone | 10,000 |
| Thebaine | 800 |
| Diacetylmorphine (Heroin) | 20 |
| **Phencyclidine (PCP 10)** | |
| 4-Hydroxyphencyclidine | 2,500 |
| Phencyclidine | 10 |
| **Oxycodone (OXY 20)** | |
| Oxycodone | 20 |
| Oxymorphone | 40 |
| Levorphanol | 10,000 |
| Hydrocodone | 1,500 |
| Hydromorphone | 10,000 |
| Naloxone | 5,000 |
| Naltrexone | 5,000 |
| **Oxycodone (OXY 40)** | |
| Oxycodone | 40 |
| Oxymorphone | 80 |
| Levorphanol | 20,000 |
| Hydrocodone | 3,000 |
| Hydromorphone | 20,000 |
| Naloxone | 10,000 |
| Naltrexone | 10,000 |
| **Oxycodone (OXY 50)** | |
| Oxycodone | 50 |
| Oxymorphone | 100 |
| Levorphanol | 25,000 |
| Hydrocodone | 3,750 |
| Hydromorphone | 25,000 |
| Naloxone | 12,500 |

| Compound | ng/mL |
|---|---|
| Naltrexone | 12,500 |
| **Cotinine (COT 20)** | |
| (-)-Cotinine | 20 |
| (-)-Nicotine | 300 |
| **Synthetic Marijuana (K2-25)** | |
| JWH-018 5-Pentanoic acid metabolite | 25 |
| JWH-073 4-butanoic acid metabolite | 25 |
| JWH-073 4-Hydroxybutyl metabolite | 250 |
| JWH-018 4-Hydroxypentyl metabolite | 200 |
| JWH-018 5-Hydroxypentyl metabolite | 250 |
| **Benzodiazepines (BZO 50)** | |
| Alprazolam | 25 |
| a-hydroxyalprazolam | 250 |
| Bromazepam | 130 |
| Chlordiazepoxide | 130 |
| Clobazam | 25 |
| Clonazepam | 65 |
| Clorazepatedipotass | 65 |
| Delorazepam | 130 |
| Desalkylflurazepam | 25 |
| Diazepam | 250 |
| RS-Lorazepamglucuronide | 25 |
| Estazolam | 1,000 |
| Flunitrazepam | 25 |
| (±) Lorazepam | 500 |
| Midazolam | 1,000 |
| Nitrazepam | 25 |
| Norchlordiazepoxide | 25 |
| Nordiazepam | 130 |
| Oxazepam | 50 |
| Temazepam | 25 |
| Triazolam | 500 |
| **Benzodiazepines (BZO 30)** | |
| Alprazolam | 15 |
| a-hydroxyalprazolam | 150 |
| Bromazepam | 75 |
| Chlordiazepoxide | 75 |
| Clobazam | 15 |
| Clonazepam | 40 |
| Clorazepatedipotass | 40 |
| Delorazepam | 75 |
| Desalkylflurazepam | 15 |
| Diazepam | 150 |
| RS-Lorazepamglucuronide | 15 |
| Estazolam | 600 |
| Flunitrazepam | 15 |
| (±) Lorazepam | 300 |
| Midazolam | 600 |
| Nitrazepam | 15 |
| Norchlordiazepoxide | 15 |
| Nordiazepam | 75 |
| Oxazepam | 30 |
| Temazepam | 15 |
| Triazolam | 300 |
| **Benzodiazepines (BZO 20)** | |
| Alprazolam | 10 |

| Compound | ng/mL |
|---|---|
| a-hydroxyalprazolam | 100 |
| Bromazepam | 50 |
| Chlordiazepoxide | 50 |
| Clobazam | 10 |
| Clonazepam | 25 |
| Clorazepatedipotass | 25 |
| Delorazepam | 50 |
| Desalkylflurazepam | 10 |
| Diazepam | 100 |
| RS-Lorazepamglucuronide | 10 |
| Estazolam | 400 |
| Flunitrazepam | 10 |
| (±) Lorazepam | 200 |
| Midazolam | 400 |
| Nitrazepam | 10 |
| Norchlordiazepoxide | 10 |
| Nordiazepam | 50 |
| Oxazepam | 20 |
| Temazepam | 10 |
| Triazolam | 200 |
| **Benzodiazepines (BZO 10)** | |
| Alprazolam | 10 |
| a-hydroxyalprazolam | 80 |
| Bromazepam | 40 |
| Chlordiazepoxide | 40 |
| Clobazam | 10 |
| Clonazepam | 20 |
| Clorazepatedipotass | 20 |
| Delorazepam | 40 |
| Desalkylflurazepam | 10 |
| Diazepam | 80 |
| RS-Lorazepamglucuronide | 10 |
| Estazolam | 300 |
| Flunitrazepam | 10 |
| (±) Lorazepam | 150 |
| Midazolam | 300 |
| Nitrazepam | 10 |
| Norchlordiazepoxide | 10 |
| Nordiazepam | 40 |
| Oxazepam | 10 |
| Temazepam | 10 |
| Triazolam | 150 |
| **Methadone (MTD 30)** | |
| Methadone | 30 |
| Disopyramide | 400 |
| (+)-Chlorpheniramine | 6,250 |
| LAAM | 200 |
| Doxylamine | 12,500 |
| Nor-LAAM | 12,500 |
| **Methadone (MTD 50)** | |
| Methadone | 50 |
| Disopyramide | 700 |
| (+)-Chlorpheniramine | 10,000 |
| LAAM | 350 |
| Doxylamine | 20,000 |
| Nor-LAAM | 20,000 |

| Compound | ng/mL |
|---|---|
| **Methylenedioxymethamphetamine (MDMA 50)** | |
| (±) 3,4-Methylenedioxy-methamphetamine HCl (MDMA) | 50 |
| (±) 3,4-Methylenedioxy-amphetamine HCl (MDA) | 300 |
| 3,4-Methylenedioxyethyl-amphetamine (MDE) | 30 |
| l-Methamphetamine | 25,000 |
| **Methylenedioxymethamphetamine (MDMA 75)** | |
| (±) 3,4-Methylenedioxy-methamphetamine HCl (MDMA) | 75 |
| (±) 3,4-Methylenedioxy-amphetamine HCl (MDA) | 450 |
| 3,4-Methylenedioxyethyl-amphetamine (MDE) | 45 |
| l-Methamphetamine | 37,500 |
| **Ketamine (KET 50)** | |
| Ketamine | 50 |
| Tetrahydrozoline | 20 |
| Benzphetamine | 1,250 |
| d-Methamphetamine | 1,250 |
| (+)Chlorpheniramine | 1,250 |
| l-Methamphetamine | 2,500 |
| Clonidine | 5,000 |
| Methoxyphenamine | 625 |
| Disopyramide | 625 |
| d-Norpropoxyphene | 625 |
| 4-Hydroxyphencyclidine | 2,500 |
| (+)3,4-Methylendioxymethamphetamine (MDMA) | 5,000 |
| Mephentermine | 1,250 |
| Phencyclidine | 625 |
| (1R, 2S) - (-)-Ephedrine | 5,000 |
| Promazine | 1,250 |
| EDDP | 2,500 |
| Promethazine | 1,250 |
| Levorphanol | 2,500 |
| Thioridazine | 2,500 |
| MDE | 2,500 |
| Meperidine | 1,250 |
| Dextromethorphan | 75 |
| Pentazocine | 1,250 |
| **Ketamine (KET 100)** | |
| Ketamine | 100 |
| Tetrahydrozoline | 40 |
| Benzphetamine | 2,500 |
| d-Methamphetamine | 2,500 |
| (+)Chlorpheniramine | 2,500 |
| l-Methamphetamine | 5,000 |
| Clonidine | 10,000 |
| Methoxyphenamine | 1,300 |
| Disopyramide | 1,300 |
| d-Norpropoxyphene | 1,300 |
| 4-Hydroxyphencyclidine | 5,000 |
| (+)3,4-Methylendioxymethamphetamine (MDMA) | 10,000 |
| Mephentermine | 2,500 |
| Phencyclidine | 1,300 |
| (1R, 2S) - (-)-Ephedrine | 10,000 |
| Promazine | 2,500 |
| EDDP | 5,000 |
| Promethazine | 2,500 |

| Compound | ng/mL |
|---|---|
| Levorphanol | 5,000 |
| Thioridazine | 5,000 |
| MDE | 5,000 |
| Meperidine | 2,500 |
| Dextromethorphan | 150 |
| Pentazocine | 2,500 |
| **Ketamine (KET 150)** | |
| Ketamine | 150 |
| Tetrahydrozoline | 60 |
| Benzphetamine | 3,750 |
| d-Methamphetamine | 3,750 |
| (+)Chlorpheniramine | 3,750 |
| l-Methamphetamine | 7,500 |
| Clonidine | 15,000 |
| Methoxyphenamine | 2,000 |
| Disopyramide | 2,000 |
| d-Norpropoxyphene | 2,000 |
| 4-Hydroxyphencyclidine | 7,500 |
| (+) 3,4-Methylendioxymethamphetamine (MDMA) | 15,000 |
| Mephentermine | 3,750 |
| Phencyclidine | 2,000 |
| (1R, 2S) - (-)-Ephedrine | 15,000 |
| Promazine | 3,750 |
| EDDP | 7,500 |
| Promethazine | 3,750 |
| Levorphanol | 7,500 |
| Thioridazine | 7,500 |
| MDE | 7,500 |
| Meperidine | 3,750 |
| Dextromethorphan | 225 |
| Pentazocine | 3,750 |
| **Barbiturates (BAR 50)** | |
| Amobarbital | 833 |
| 5,5-Diphenylhydantoin | 1,333 |
| Allobarbital | 100 |
| Barbital | 1,333 |
| Talbutal | 33 |
| Cyclopentobarbital | 5,000 |
| Pentobarbital | 1,333 |
| Alphenol | 100 |
| Aprobarbital | 83 |
| Butabarbital | 33 |
| Butalbital | 1,333 |
| Butethal | 83 |
| Phenobarbital | 50 |
| Secobarbital | 50 |
| **Buprenorphine (BUP 10)** | |
| Buprenorphine 3-D-Glucuronide | 50 |
| Norbuprenorphine 3-D-Glucuronide | 100 |
| Buprenorphine | 10 |
| Norbuprenorphine | 50 |
| **Buprenorphine (BUP 5)** | |
| Buprenorphine 3-D-Glucuronide | 25 |
| Norbuprenorphine 3-D-Glucuronide | 50 |
| Buprenorphine | 5 |
| Norbuprenorphine | 25 |

| Compound | ng/mL |
|---|---|
| **Tramadol (TML 30)** | |
| n-Desmethyl-cis-tramadol | 60 |
| d,l-O-Desmethylvenlafaxine | 15,000 |
| o-Desmethyl-cis-tramadol | 3,000 |
| Phencyclidine | 30,000 |
| Cis-tramadol | 30 |
| Procyclidine | 30 |
| **6-Monoacethylmorphine (6-MAM 10)** | |
| 6-Monoacethylmorphine | 10 |
| Morphine | 100,000 |
| **Fentanyl (FYL 50)** | |
| Alfentanyl | 1,500,000 |
| Fenfluramine | 125,000 |
| Norfentanyl | 10 |
| Buspirone | 37,500 |
| Fentanylf | 50 |
| Sufentanyl | 125,000 |
| **Fentanyl (FYL 20)** | |
| Alfentanyl | 600,000 |
| Fenfluramine | 50,000 |
| Norfentanyl | 8 |
| Buspirone | 37,500 |
| Fentanyl | 20 |
| Sufentanyl | 50,000 |
| **Fentanyl (FYL 10)** | |
| Alfentanyl | 300,000 |
| Fenfluramine | 25,000 |
| Norfentanyl | 5 |
| Buspirone | 18,750 |
| Fentanyl | 10 |
| Sufentanyl | 25,000 |
| **Carfentanyl (CFYL 50)** | |
| Carfentanyl | 50 |
| Sufentanil | 300 |
| Ramifentanil | 500 |
| Fentanyl | 25 |
| (±)cis-3-Methylfentanyl | 50,000 |
| Butylfentanyl | 200 |
| **3, 4-methylenedioxypyrovalerone (MDPV 300)** | |
| 3, 4-methylenedioxypyrovalerone | 300 |
| **alpha-Pyrrolidinovalerophenone (α-PVP 300)** | |
| alpha-Pyrrolidinovalerophenone | 300 |
| **Lysergic Acid Diethylamide (LSD 10)** | |
| Lysergic Acid Diethylamide | 10 |

## Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds spiked into drug-free oral fluid. The following compounds demonstrated no false positive results on the Rapid Response® Saliva Drug Test Stick when tested with at concentrations up to 100 µg/mL.

| | |
|---|---|
| Acetaminophen | N-Acetylprocainamide |
| Aminopyrine | Ampicillin |
| Apomorphine | Atropine |
| Benzoic acid | d/l-Brompheniramine |
| Chloral-hydrate | Chlorothiazide |

| | |
|---|---|
| Chlorpromazine | Cholesterol |
| Cortisone | Creatinine |
| Dextromethorphan | Diflunisal |
| Diphenhydramine | β-Estradiol |
| Ethyl-p-aminobenzoate | Erythromycin |
| Furosemide | Hemoglobin |
| Hydrochlorothiazide | o-Hydroxyhippuric acid |
| Ibuprofen | d/l-Isoproterenol |
| Acetophenetidin | Acetylsalicylic acid |
| Amoxicillin | l-Ascorbic acid |
| Aspartame | Benzilic acid |
| Benzphetamine | Caffeine |
| Chloramphenicol | Sodium chloride |
| d/l-Chloropheniramine | Chloroquine |
| Clonidine | l-Cotinine |
| Deoxycorticosterone | Diclofenac |
| Digoxin | l -Ψ-Ephedrine |
| Estrone-3-sulfate | l(−)-Epinephrine |
| Fenoprofen | Gentisic acid |
| Hydralazine | Hydrocortisone |
| p-Hydroxytyramine | Iproniazid |
| Isoxsuprine | Labetalol |
| Meperidine | Methylphenidate |
| Naproxen | Nifedipine |
| d-Norpropoxyphene | d/l-Octopamine |
| Oxolinic acid | Papaverine |
| Pentazocine hydrochloride | Phenelzine |
| Phenylpropanolamine | Prednisone |
| d-Propoxyphene | Quinacrine |
| Quindine | Salicylic acid |
| Zomepirac | Toothpaste |
| Sulfamethazine | Tetracycline |
| Tetrahydrocortisone 3 (β-D-glucuronide) | Thioridazine |
| Tolbutamide | Trifluoperazine |
| d/l-Tryptophan | Uric acid |
| Ketoprofen | Loperamide |
| Meprobamate | Nalidixic acid |
| Niacinamide | Norethindrone |
| Noscapine | Oxalic acid |
| Oxymetazoline | Penicillin-G |
| Perphenazine | Trans-2-phenylcyclopropylamine hydrochloride |
| Prednisolone | d/l-Propranolol |
| d-Pseudoephedrine | Quinine |
| Ranitidine | Serotonin |
| Sulindac | Tetrahydrocortisone 3-acetate |
| Thiamine | d/l-Tyrosine |
| Triamterene | Trimethoprim |
| Tyramine | Verapamil |
| Glucose | Mouthwash |

## Alcohol Performance Characteristics

### Analytical Sensitivity

The detection limit on the Oral Fluid Alcohol Rapid Test is from 0.02% to 0.30% for approximate relative blood alcohol level. The cutoff level of the Oral Fluid Alcohol Rapid Test can vary based on local regulations and laws. Test results can be compared to reference levels with colour chart on the foil package.

### Analytical Specificity

The Oral fluid Alcohol Rapid Test will react with methyl, ethyl and allyl alcohols.[19]

### Interfering Substances

The following substances have been tested and may interfere with the Oral fluid Alcohol Rapid Test at the concentration listed when using samples other than oral fluid. The named substances do not normally appear in sufficient quantity in oral fluid to interfere with the test.

| Substances | Concentration Level |
|---|---|
| Peroxidases | 0.5 mg/dL |
| Hydrogen peroxide | 10 ppm |
| Creatinine | 200 mg/dL |
| Ascorbic acid | 5 mg/dL |
| Tannic acid | 10 mg/dL |
| Calcium Chloride | 100 mg/dL |
| Mercaptans | 10 mg/dL |
| NaCl | 1,000 mg/dL |
| Oxalic acid | 15 mg/dL |
| Uric Acid | 15 mg/dL |
| L-dopa | 10 mg/dL |
| L-methyldopa | 10 mg/dL |
| Methampyrone | 8 mg/dL |
| KCl | 1,000 mg/dL |
| Sodium hypochlorite | 80 ppm |
| Pyrogallol | 15 mg/dL |
| Glucose | 1,000 mg/dL |
| Tosylates | 10 mg/dL |
| Urea | 1,000 mg/dL |
| Bilirubin | 4 mg/dL |

### Precision

Negative saliva and control solutions were tested two replicates each day for five consecutive days at three sites using three different lots of Oral fluid Alcohol Rapid Test. There is no significant difference within runs, between days, sites, lots and operators.

## Bibliography


1. Moolchan, E., et al, "Saliva and Plasma Testing for Drugs of Abuse: Comparison of the Disposition and Pharmacological Effects of Cocaine", Addiction Research Center, IRP, NIDA, NIH, Baltimore, MD. As presented at the SOFT-TIAFT meeting October 1998.
2. Kim, I, et al, "Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration", ClinChem, 2002 Sept.; 48 (9), pp 1486-96.
3. Schramm, W. et al, "Drugs of Abuse in Saliva: A Review," J Anal Tox, 1992 Jan-Feb; 16 (1), pp 1-9.
4. McCarron, MM, et al, "Detection of Phencyclidine Usage by Radioimmunoassay of Saliva," J Anal Tox. 1984 Sep-Oct.; 8 (5), pp 197-201.
5. International Narcotics Control Board.Report of the International Narcotics Control Board for 2009[R].New York：UN，2010.
6. Lane JC, Tennison MB, Lawless ST, et al.Movement disorder after withdrawal of fentanyl infusion.J Pediatr，1991，119(4)：649-651.
7. Dominguez KD, Lomako DM，Katz RW，et al. Opioid withdraw in critically ill neonates.Ann Pharmacotherm，2003，37(4)：473-477.
8. European Monitoring Centre for Drugs and Drug Addiction.Annual Report 2009[R].Lisbon：EMCDDA，2010
9. Stanley, Theodore H.; Egan, Talmage D.; Aken, Hugo Van (February 2008). "A Tribute to Dr. Paul A. J. Janssen: Entrepreneur Extraordinaire, Innovative Scientist, and Significant Contributor to Anesthesiology". Anesthesia & Analgesia. 106 (2): 451–462.
10. Vos, V. De (22 July 1978). "Immobilisation of free-ranging wild animals using a new drug". Veterinary Record. 103 (4): 64–68.Dominguez KD, Lomako DM，Katz RW，et al. Opioid withdraw in critically ill neonates.Ann Pharmacotherm，2003，37(4)：473-477
11. Mounteney, Jane; Giraudon, Isabelle; Denissov, Gleb; Griffiths, Paul (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". International Journal of Drug Policy. 26 (7): 626–631.
12. Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New York, NY. 1991, 216
13. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed.
14. Waugh; et al. (2013). "Deaths Involving the Recreational Use of α-PVP (α-pyrrolidinopentiophenone)" (PDF). AAFS Proceedings. Abstract K16.
15. Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New York, NY. 1991, 216
16. Volpicellim, Joseph R., M.D., Ph.D.: Alcohol Dependence: Diagnosis, Clinical Aspects and Biopsychosocial Causes., Substance Abuse Library, University of Pennsylvania, 1997.
17. Jones, A.W.: Inter-and intra individual variations in the saliva/blood alcohol ratio during ethanol metabolism in man., Clin. Chem. 25, 1394-1398, 1979.
18. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488
19. MaCall, L.E.L., Whiting, B., Moore, M.R. and Goldberg, A.: Correlation of ethanol concentrations in blood and saliva. Clin.Sci., 56, 283-286, 1979.


## Glossary of Symbols

| | | | | | |
|---|---|---|---|---|---|
| | Consult instructions for use | Σ | Tests per Kit | UDI | Unique device identifier |
| 35.6°F 2°C 86°F 30°C | Store between 35.6°F to 86°F (2-30°C) | | Use by | | Do Not Reuse |
| LOT | Lot Number | IVD | For *in vitro* diagnostic use only | REF | Catalogue # |
| | Manufacturer | | | | |


**BTNX Inc.**
722 Rosebank Road,
Pickering, ON L1W 4B2
Canada
**Technical Support: 1-888-339-9964**